- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Sera Prognostics Appoints Tiffany Inglis As CMO | - | RTTNews | ||
| 01.10. | Sera Prognostics appoints Dr. Tiffany Inglis as chief medical officer | 1 | Investing.com | ||
| 01.10. | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 63 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 05.09. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.09. | Sera Prognostics forciert Kommerzialisierung des PreTRM-Tests | 1 | Investing.com Deutsch | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Sera Prognostics übertrifft Gewinnprognose - Aktie steigt trotz schwachem Umsatz | 3 | Investing.com Deutsch | ||
| 07.08. | Sera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilots | 1 | Seeking Alpha | ||
| 06.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 60 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 05.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.05. | Sera Prognostics names Lee Anderson as new CCO | 1 | Investing.com | ||
| 08.05. | Sera Prognostics ernennt Lee Anderson zum neuen CCO | 9 | Investing.com Deutsch | ||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 200 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 292 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 207 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 148 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,675 | +2,45 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| OCUGEN | 1,324 | -9,81 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,920 | +0,12 % | Down 44%, Should You Buy the Dip on Viking Therapeutics? | ||
| COSCIENS BIOPHARMA | 2,220 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings sichert sich neue Finanzierung und Option auf bis zu 5 Mio. US-Dollar | ||
| BIOCRYST PHARMACEUTICALS | 6,006 | -3,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,270 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| IBIO | 0,700 | +2,94 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,700 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ARBUTUS BIOPHARMA | 3,540 | -0,11 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| CARDIFF ONCOLOGY | 1,940 | +1,25 % | Onvansertib: Cardiff Oncology überzeugt mit starken Phase-II-Daten bei Darmkrebs | ||
| ALDEYRA | 4,579 | -1,25 % | Jefferies erhöht Kursziel für Aldeyra Therapeutics nach FDA-Annahme auf 7 US-Dollar | ||
| MANNKIND | 4,421 | +5,09 % | MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes | If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action... ► Artikel lesen | |
| TRAWS PHARMA | 2,920 | -2,99 % | Traws Pharma, Inc.: Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives | NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,514 | +4,92 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,150 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.